Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Transplantation. 2022 Jul 22;106(8):1647–1655. doi: 10.1097/TP.0000000000004058

Figure 3:

Figure 3:

Consensus opinion recommendations regarding “for cause” monitoring in the setting of increasing fasting glucose and/or HbA1c levels (blue bars) in islet allografts. Strongly recommended >75%; Recommended 60-75%; Suggested 45-60%. (A) Static and dynamic metabolic monitoring and (B) immunologic monitoring.